Previous 10 | Next 10 |
Healthcare companies are continuously looking for new treatment options for patients. One in particular, COMPASS Pathways (CMPS), is focused on using psilocybin therapy treat depression. The stock has generated a lot of interest, but is down 25% for the year. Is it time to buy? Read more to f...
NetworkNewsWire Editorial Coverage : Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lysergic acid diethylamide) and MDMA (meth...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As a treatment for mood disorders, psychedelics-inspired medicine isn’t quite in the mainstream yet. Undoubtedly, Compass Pathways (NASDAQ: CMPS ) and CMPS stock holders would like to see more progress in ...
Nearly 10 million people struggle with Parkinson’s disease at the moment.While there is no cure for Parkinson’s disease just yet, treatments such as L-dopa, or Levodopa can help control the symptoms, including stiffness, weakness, and rigidity. Unfortunately, even long-term ...
This is Psychedellux, the week’s top business headlines in the psychedelics industry. COMPASS Pathways plc (Nasdaq: CMPS) reported its financial results for the first quarter of 2021 as the company continues to plug away at research. The net loss was $12.7 million...
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q1 2021 Earnings Call May 13, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q1 2021 Earnings Call Transcript
COMPASS Pathways plc (Nasdaq: CMPS) reported its financial results for the first quarter of 2021. The net loss was $12.7 million, or $0.35 loss per share (after including non-cash share-based compensation expense of $1.7 million), versus $8.6 million, or $0.93 loss per share, duri...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 13, 2021 – Psychedelics are quietly being used in clinical settings on small numbers of patients, but they are moving quickly toward medical approval. The FDA recently approved large...
COMPASS Pathways ADS (CMPS): Q1 GAAP EPS of -$0.35.Pro-forma cash and cash equivalents was $179.5 million as of March 31, 2021, compared with $190.3 million at December 31, 2020.Press Release For further details see: COMPASS Pathways ADS reports Q1 results
LONDON, May 13, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2021 and ga...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...